D

I

DESMOULINS , I.

Last name: DESMOULINS

First name: I.

May 2018 (v1)

Journal article

Metadata-only

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

Jacquet, E. Lardy-Cléaud, A. Pistilli, B.

BACKGROUND:For hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines recommend endocrine therapy as first-line treatment, except in case of 'visceral crisis'. In the latter case, chemotherapy is preferred. Few studies have compared these two strategies....

Uploaded on: December 4, 2022
2021 (v1)

Journal article

Metadata-only

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

Grinda, T. Antoine, A. Jacot, W.

BACKGROUND: Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients who initiated...

Uploaded on: December 4, 2022